Drug Profile
KAI 1678
Alternative Names: KAI-1678Latest Information Update: 19 Aug 2015
Price :
$50
*
At a glance
- Originator KAI Pharmaceuticals
- Developer Amgen
- Class Anti-inflammatories; Non-opioid analgesics; Peptides; Small molecules
- Mechanism of Action Protein kinase C epsilon inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neuropathic pain; Postoperative pain
Most Recent Events
- 05 Jul 2012 KAI Pharmaceuticals has been acquired by Amgen
- 22 Apr 2010 KAI Pharmaceuticals completes a phase IIa trial (NCT01106716) in Neuropathic pain in Australia
- 21 Oct 2009 Pharmacodynamics data from a preclinical study in Neuropathic pain presented at the 39th Annual Meeting of the Society for Neuroscience (SfN-2009)